12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada	Policies or Program

  Subject matters in previous versions

  • Economic Development
  • Government Procurement
  • Health
  • Research and Development
  • Science and Technology

  Subject matters added through a communication report:

  • Economic Development
  • Government Procurement
  • Health
  • Research and Development
  • Science and Technology

Government Institutions

• Federal Economic Development Agency for Southern Ontario (FedDev)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Prairies Economic Development Canada (PrairiesCan)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Laura Fitzgerald, Associate Director, External Affairs | No public offices held
• Patricia Gauthier, General Manager, Resilience Program and Markets | No public offices held
• Leslie Madden, Federal Affairs & Policy Lead | No public offices held
• James Mansi, VP and Head, Medical Strategy, Resilience Markets & CMD Canada | No public offices held
• Roger Ngassam, Site Head, Canada | No public offices held
• Rahbar Rahimpour, Director, R&D Strategic Alliances | No public offices held
• Stefan Raos, General Manager | No public offices held
• Lisa Wise-Milestone, Associate Director, Strategic Partnerships | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Laura Fitzgerald, Associate Director, Government Affairs and Policy | No public offices held
  • Shehzad Iqbal, Sr. Medical Director | No public offices held
  • Kavisha Jayasundara, Director, Market Access and Innovative Partnerships | No public offices held
  • Leslie Madden, Sr. Director, Regulatory Science and Quality Assurance | No public offices held
  • Lisa Wise-Milestone, Strategic Lead for Pandemic Preparedness Initiative | No public offices held